Dendreon reports Q4 EPS (26c), consensus (56c) Reports Q4 revenue $85.5M, consensus $82.88M. The company expects to reduce cost of goods sold to below 50% of net product revenue in the beginning of 3Q13. Expects to begin to see net benefits associated with the restructuring initiatives to begin to appear in financial results as early as 1H13, with full benefits realized in Q313. Says actively evaluating partnering strategies for European expansion; continuing to enroll patients in the sipuleucel-T European Union open-label study; expect a mid-2013 regulatory decision in Europe.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.